One Stop Solution For In-Depth Market Research Reports

詳細な市場調査レポートのワンストップソリューション

Home    >    HEALTHCARE AND PHARMACEUTICALS   >   Preimplantation Genetic Testing Market

着床前遺伝子検査市場ー業界洞察、主要プレーヤー・企業別、成長機会別、最新傾向別、開発別、主要な成長ドライバー別、主要な課題別によってセグメンテーション、予測 2022年


[ 英語タイトル ] Preimplantation Genetic Testing Market by Type (Genetic Diagnosis/Genetic Screening), Technology (NGS, PCR, FISH, CGH, SNP), Products & Services, Application (Aneuploidy, Translocations), End User (Fertility Clinics, Research) - Forecast to 2022


Product Code : MNMHC00108480
Survey : MarketsandMarkets
Publish On : August, 2021
Category : Healthcare and Pharmaceuticals
Study Area : Global
Report format : PDF
Sales price option (consumption tax not included)
Single User USD5650 / Question Form
5 User USD6650 / Question Form
Enterprise User USD10000 / Question Form

[Report Description]

“Preimplantation genetic testing market projected to grow at a CAGR of 10.0%”
The global preimplantation genetic testing market is expected to reach USD 541.8 million by 2022 from USD 336.4 million in 2017, at a CAGR of 10.0%. Growing rate of infertility across the globe, increasing public-private investments in the field of preimplantation genetic testing, rising number of fertility clinics worldwide, technological advancements in the field of genetic analysis, and high risk of chromosomal abnormalities in the fetus with increasing maternal age are some of the key factors driving the growth of this market. However, the high procedural cost associated with preimplantation genetic testing and unsupportive government regulations are the factors restraining the growth of this market

“Next-generation Sequencing is expected to grow at the highest CAGR during 2017 to 2022”
By technology, the preimplantation genetic testing market covers next-generation sequencing (NGS), polymerase chain reaction (PCR), fluorescence in situ hybridization (FISH), comparative genomic hybridization (CGH), and single-nucleotide polymorphism (SNP). The NGS segment is expected to grow at the highest CAGR during 2017 to 2022, owing to benefits like reduced cost, better ability to detect an embryo with differing results (mosaicism), enhanced detection of structural abnormalities such as chromosomes with missing or duplicate segments, and reduction in human errors due to increased automation.

“The maternity centers & fertility clinics to dominate the global preimplantation genetic testing market during the forecast period”
On the basis of end users, the preimplantation genetic testing market is segmented into maternity centers & fertility clinics; hospitals, diagnostic labs, and service providers; and research laboratories & academic institutes. The maternity centers & fertility clinics segment accounted for the largest share of the global preimplantation genetic testing market in 2016 owing to the high success rate of treatments at fertility centers.

“APAC is projected to witness the highest growth during the forecast period “
While North America accounted for the largest share of the market in 2016, Asia-Pacific is expected to register the highest growth rate during the forecast period from 2017 to 2022. This is owing to the focus of key market players in this region, growing number of ART & IVF procedures in the region, continuous decline in average fertility rate, government initiatives for expansion and modernization of healthcare infrastructure across respective countries, and growing medical tourism across APAC countries.

Breakdown of supply-side primary interviews: by company type, designation, and region:
• By Company Type - Tier 1 –50%, Tier 2 –33% and Tier 3 –17%
• By Designation – C level – 17%, Director level – 50%, Others – 33%
• By Region – North America - 34%, Europe – 26%, APAC – 35%, RoW – 5%

The major players in the market are Illumina, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), PerkinElmer, Inc. (U.S.), CooperSurgical, Inc. (U.S.), Beijing Genomics Institute (BGI) (China), Abbott Laboratories (U.S.), Natera, Inc. (U.S.), Genea Limited (Australia), Rubicon Genomics, Inc. (U.S.), and Oxford Gene Technology (U.K.), among others.

Research Coverage
This report studies the preimplantation genetic testing market based on technology, product & service, procedure type, application, and end user. The report also analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting market growth. It evaluates opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micromarkets with respect to their growth trends, prospects, and contributions to the total market. The report forecasts the revenue of the market segments with respect to four main regions.

Reasons to Buy the Report:
This research focuses on various levels of analysis—industry trends, vendor dive analysis of 25 market players, and company profiles of top 15 market players—which together comprise and discuss basic views on the competitive landscape, emerging and high-growth segments of the preimplantation genetic testing market, and high-growth regions and countries and their respective drivers, restraints, challenges, and opportunities.

The report provides insights on the following pointers:

• Market Penetration: Comprehensive information on business strategies adopted by the major players in the preimplantation genetic testing market. The report analyzes the preimplantation genetic testing market based on technology, product & service, procedure type, application, end user, and region

• Product Development/Innovation: Detailed insights on the upcoming technologies, research and development activities, and product launches in the preimplantation genetic testing market

• Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various preimplantation genetic testing products across geographies

• Market Diversification: Exhaustive information about new products and services, untapped geographies, recent developments, and investments in the preimplantation genetic testing market

• Competitive Assessment: In-depth assessment of market shares, strategies, products and services, distribution networks, and manufacturing capabilities of leading players in the preimplantation genetic testing market

TABLE OF CONTENTS

1 INTRODUCTION 17
1.1 OBJECTIVES OF THE STUDY 17
1.2 MARKET DEFINITION 17
1.3 MARKETS COVERED 18
1.3.1 YEARS CONSIDERED FOR THE STUDY 18
1.4 CURRENCY USED 19
1.5 LIMITATIONS 19
1.6 STAKEHOLDERS 19
2 RESEARCH METHODOLOGY 20
2.1 RESEARCH METHODOLOGY STEPS 21
2.1.1 SECONDARY RESEARCH 21
2.1.1.1 Key data from secondary sources 21
2.1.2 PRIMARY RESEARCH 23
2.1.2.1 Breakdown of primaries 23
2.1.2.2 Key data from primary sources 24
2.2 MARKET SIZE ESTIMATION 25
2.2.1.1 Research methodology: bottom-up approach 25
2.2.1.2 Research methodology: top-down approach 26
2.3 RESEARCH DESIGN 27
2.4 DATA VALIDATION AND TRIANGULATION 28
2.4.1 ASSUMPTIONS FOR THE STUDY 29
3 EXECUTIVE SUMMARY 30
4 PREMIUM INSIGHTS 38
4.1 PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING: MARKET OVERVIEW 38
4.2 GEOGRAPHIC ANALYSIS: PREIMPLANTATION GENETIC DIAGNOSIS AND
SCREENING MARKET, BY TECHNOLOGY (2016) 39
4.3 PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET, BY APPLICATION, 2017 VS. 2022 40
4.4 PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET,
BY PRODUCT & SERVICE (2017 VS. 2022) 41
4.5 GEOGRAPHICAL SNAPSHOT OF THE PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET 42

5 MARKET OVERVIEW 43
5.1 INTRODUCTION 44
5.2 MARKET EVOLUTION: PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING TECHNOLOGIES 44
5.3 MARKET DYNAMICS 45
5.3.1 MAJOR MARKET DRIVERS 46
5.3.1.1 Declining fertility rates worldwide 46
5.3.1.2 Increasing public-private investments in the field of preimplantation genetic testing 47
5.3.1.3 Rising number of fertility clinics worldwide 48
5.3.1.4 Technological advancements in the field of genetic analysis 49
5.3.1.5 High risk of chromosomal abnormalities with advancing maternal age 50
5.3.2 MAJOR MARKET RESTRAINTS 51
5.3.2.1 High procedural cost associated with preimplantation genetic testing 51
5.3.2.2 Unfavorable government regulations 52
5.3.3 MAJOR MARKET OPPORTUNITIES 53
5.3.3.1 Growth opportunities in emerging markets 53
5.3.3.1.1 Improving healthcare infrastructure 53
5.3.3.1.2 Growing medical tourism 54
5.3.3.1.3 Growth initiatives by key market players 55
5.3.3.2 Growing awareness on assisted reproduction techniques 55
5.3.4 MAJOR MARKET CHALLENGES 56
5.3.4.1 Socioethical concerns regarding preimplantation genetic testing 56
5.3.4.2 Procedural limitations of preimplantation genetic testing with advancing age 57
6 INDUSTRY INSIGHTS 58
6.1 VALUE CHAIN ANALYSIS 58
6.2 PORTER’S FIVE FORCES ANALYSIS 59
6.3 REGULATORY SCENARIO 60
7 PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET,
BY PROCEDURE TYPE 62
7.1 INTRODUCTION 63
7.2 PREIMPLANTATION GENETIC SCREENING 64
7.3 PREIMPLANTATION GENETIC DIAGNOSIS 65

8 PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET,
BY TECHNOLOGY 66
8.1 INTRODUCTION 67
8.2 NEXT-GENERATION SEQUENCING 68
8.3 POLYMERASE CHAIN REACTION 69
8.4 FLUORESCENCE IN SITU HYBRIDIZATION 70
8.5 COMPARATIVE GENOMIC HYBRIDIZATION 71
8.6 SINGLE-NUCLEOTIDE POLYMORPHISM 72
9 PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET,
BY PRODUCT AND SERVICE 73
9.1 INTRODUCTION 74
9.2 REAGENTS AND CONSUMABLES 75
9.3 INSTRUMENTS 76
9.4 SOFTWARE AND SERVICES 78
10 PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET,
BY APPLICATION 79
10.1 INTRODUCTION 80
10.2 ANEUPLOIDY 81
10.3 STRUCTURAL CHROMOSOMAL ABNORMALITIES 83
10.3.1 TRANSLOCATIONS 84
10.3.2 DELETIONS 85
10.3.3 DUPLICATIONS 86
10.3.4 INVERSIONS 87
10.4 SINGLE GENE DISORDERS 88
10.5 X-LINKED DISORDERS 89
10.6 HLA TYPING 90
10.7 GENDER IDENTIFICATION 91
11 PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET,
BY END USER 92
11.1 INTRODUCTION 93
11.2 MATERNITY CENTERS & FERTILITY CLINICS 94
11.3 HOSPITALS, DIAGNOSTIC LABS, AND SERVICE PROVIDERS 95
11.4 RESEARCH LABORATORIES & ACADEMIC INSTITUTES 96

12 PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET,
BY REGION 98
12.1 INTRODUCTION 99
12.2 NORTH AMERICA 101
12.2.1 U.S. 107
12.2.2 CANADA 109
12.3 EUROPE 111
12.3.1 GERMANY 116
12.3.2 U.K. 117
12.3.3 FRANCE 118
12.3.4 REST OF EUROPE 119
12.4 ASIA-PACIFIC 121
12.4.1 CHINA 126
12.4.2 JAPAN 127
12.4.3 INDIA 128
12.4.4 REST OF ASIA-PACIFIC 129
12.5 REST OF THE WORLD 130
13 COMPETITIVE LANDSCAPE 136
13.1 INTRODUCTION 136
13.2 LEADING PLAYERS IN THE PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING MARKET 137
13.3 COMPETITIVE SITUATION AND TRENDS 138
13.3.1 AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS 139
13.3.2 PRODUCT LAUNCHES AND APPROVALS 140
13.3.3 ACQUISITIONS 141
13.3.4 EXPANSIONS 141
13.3.5 OTHER DEVELOPMENTS 142
13.4 GLOBAL PREIMPLANTATION GENETIC DIAGNOSIS AND SCREENING COMPETITIVE LEADERSHIP MAPPING, 2017 143
13.4.1 VISIONARY LEADERS 143
13.4.2 INNOVATORS 143
13.4.3 DYNAMIC DIFFERENTIATORS 143
13.4.4 EMERGING COMPANIES 143
13.5 COMPETITIVE LEADERSHIP MAPPING 145
13.5.1 STRENGTH OF PRODUCT PORTFOLIO (FOR 25 PLAYERS) 145
13.5.2 BUSINESS STRATEGY EXCELLENCE (FOR 25 PLAYERS) 146
*Top 25 companies analysed for this study are - Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Agilent Technologies, Inc. (U.S.), PerkinElmer, Inc. (U.S.), CooperSurgical, Inc. (U.S.), Abbott Laboratories (U.S.), Natera, Inc. (U.S.), Rubicon Genomics, Inc. (U.S.), Oxford Gene Technology (U.K.), Yikon Genomics (China), SciGene (U.S.), Beijing Genomics Institute (China), Good Start Genetics (U.S.), Invicta Genetics (Poland), CombiMatrix Corporation (U.S.), Genea Limited (Australia), Progenesis (U.S.), Arrayit Corporation (U.S.), Macrogen, Inc. (South Korea), Elucigene Diagnostics (U.K.), Reproductive Health Science Ltd. (Australia), Singlera Genomics, Inc. (U.S.), iGenomix (Spain), Source BioScience (U.K.), PacGenomics (U.S.)

14 COMPANY PROFILES 147
(Overview, Products and Services, Financials, Strategy & Development)*
14.1 TOP PRODUCT MANUFACTURERS 147
14.1.1 ILLUMINA, INC. 147
14.1.2 THERMO FISHER SCIENTIFIC INC. 151
14.1.3 AGILENT TECHNOLOGIES, INC. 154
14.1.4 PERKINELMER, INC. 157
14.1.5 COOPERSURGICAL, INC. (A SUBSIDIARY OF THE COOPER COMPANIES, INC.) 160
14.1.6 ABBOTT LABORATORIES 164
14.1.7 NATERA, INC. 166
14.1.8 RUBICON GENOMICS (A SUBSIDIARY OF TAKARA BIO USA HOLDINGS, INC.) 169
14.1.9 OXFORD GENE TECHNOLOGY 172
14.1.10 YIKON GENOMICS 174
14.1.11 SCIGENE 176
14.2 TOP SERVICE PROVIDER COMPANIES 178
14.2.1 BEIJING GENOMICS INSTITUTE 178
14.2.2 GOOD START GENETICS, INC. 181
14.2.3 INVICTA GENETICS 184
14.2.4 COMBIMATRIX CORPORATION 186
14.2.5 GENEA LIMITED 189
14.2.6 PROGENESIS 191
*Details on Overview, Products and Services, Financials, Strategy & Development might not be Captured in case of Unlisted Companies.
15 APPENDIX 194
15.1 INSIGHTS OF INDUSTRY EXPERTS 194
15.2 DISCUSSION GUIDE 195
15.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 199
15.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 201
15.5 AVAILABLE CUSTOMIZATIONS 203
15.6 RELATED REPORTS 203
15.7 AUTHOR DETAILS 204

渋谷データカウント

渋谷データカウントは、最も信頼性が高く最新の調査分析レポートを確実に提供する経験豊富な調査専門家のグローバルチームが提供する、さまざまな業界のさまざまな市場調査レポートを提供する再販代理店です。

Recommended reports

+